Bacterial Isolate Identification for C. difficile Bacteriotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for recurrent Clostridium difficile disease, such as vancomycin, often lead to relapse due to pathological imbalance in the intestinal microbiota, and fecal bacteriotherapy's effectiveness is unclear due to the unknown mechanism of specific probiotic mixes.
Innovation Solution
A method for identifying and isolating bacterial isolates suitable for bacteriotherapy involves preparing a suspension from host microbiota, adding an activator for bacterial spores, and culturing under aerobic or anaerobic conditions to identify suitable bacterial isolates, which can then be used to create a medicament for repopulating the gut and treating associated infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotic treatment is used for C. difficile disease, then initial treatment effectiveness is achieved, but recurrent disease occurs due to pathological imbalance in intestinal microbiota
Solution Approach 1:
The patent applies preliminary action by administering probiotic bacteria to restore intestinal microbiota balance before the pathological imbalance fully develops or recurs. This preventive approach addresses the root cause of relapse by re-establishing a healthy microbial ecosystem that competes with C. difficile, thereby extending disease remission duration and reducing recurrence rates
Solution Approach 2:
The patent uses probiotic bacteria as an intermediary substance to mediate between the harmful C. difficile infection and the host's intestinal environment. These probiotic organisms act as biological agents that restore microbial balance, compete with pathogens for resources and attachment sites, and modulate the intestinal environment to prevent C. difficile recurrence, thereby extending treatment effectiveness beyond the initial antibiotic course
2Stability of the object's composition
If fecal bacteriotherapy is used to restore microbiota, then microbiota balance is improved, but the mechanism of specific probiotic mixes remains unclear
Solution Approach 1:
The patent applies segmentation by dividing the complex fecal microbiota into specific, identifiable probiotic bacterial strains and species. Instead of using undifferentiated fecal material, the invention isolates and characterizes individual probiotic organisms, allowing researchers to understand the specific mechanisms by which each strain contributes to microbiota restoration and C. difficile prevention, thereby reducing the information loss about therapeutic mechanisms
3Quantity of substance
If complex fecal material is used for bacteriotherapy, then microbiota diversity is maintained, but identification of specific beneficial bacterial isolates becomes difficult
Solution Approach 1:
The patent applies the taking out principle by extracting specific beneficial bacterial isolates from complex fecal material through systematic culturing and identification procedures. The invention isolates individual bacterial strains from the diverse fecal microbiota, characterizes their properties, and identifies their therapeutic potential, thereby making the detection and measurement of specific beneficial organisms possible while preserving microbiota diversity
Data Source
AI summary
A method, for the identification of bacterial isolates suitable for use in bacteriotherapy, the method comprising: (i) preparing a suspension of material collected from a host harbouring microbiota; (ii) addition of an activator of bacterial spores sufficient to allow growth of bacteria from spores present in the suspension; (iii) culturing the suspension; and (iv) identification of at least one bacterial species within the culture.